BOSTON–(BUSINESS WIRE)–Compass Therapeutics, Inc. (the Company), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it has priced an underwritten public offering to sell…

Click here to view the original article.